Pfizer Prepares For Year-End US Bevacizumab Launch
Executive Summary
Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.
You may also be interested in...
Pfizer Launches US Bevacizumab At A 23% Discount
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.
FDA Reviews Samsung Bioepis’ Bevacizumab
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.